Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.

Neevika ManoharanJungwhan ChoiChristine ChordasMary Ann ZimmermanJacqueline ScullyJessica ClymerMariella FilbinNicole J UllrichPratiti BandopadhayaySusan N ChiKee Kiat Yeo

Published in: Journal of neuro-oncology (2020)

Trametinib appears to be an effective treatment for patients with recurrent/progressive pLGG. The toxicities of this therapy warrant further investigation, with particular attention to the potential risk for intracranial hemorrhage. Early phase multi-institutional clinical trials are underway.

Keyphrases

low grade
clinical trial
multiple sclerosis
high grade
stem cells
randomized controlled trial
combination therapy
risk assessment
study protocol
mesenchymal stem cells
bone marrow
cell therapy
smoking cessation